Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Real-World Safety and Efficacy of 156 U – 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study

Fig. 2

Mean (SD) change from baseline in MSQ dimensions. Mean (SD) change from baseline in MSQ dimensions at administration visit 1 through 8. (a-b) Role-function restrictive score; (c-d) Role-function preventive; (e–f) Emotional function score. Patients treated with 155 U onabotulinumtoxinA (left) or 156–195 U (right) at 4 or more visits. MSQ = Migraine Specific Quality of Life Questionnaire; SD, standard deviation. * p < 0.001 paired t- test for change vs baseline

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us